卡格列净对2型糖尿病饮食钠摄入心肾效应的影响:CREDENCE试验事后分析
CREDENCE试验事后分析纳入2573例2型糖尿病合并慢性肾脏病(CKD)患者,按尿钠估算分为低正常钠(LNS,n=1286)和高钠(HS,n=1287)组。安慰剂组中LNS增加心衰/心血管死亡风险(adjHR 1.56,95%CI 1.10–2.23),卡格列净显著降低LNS组该风险(adjHR 0.48,95%CI 0.33–0.70)但对HS组无影响;肾脏保护作用与钠摄入无关。
要点
- 低正常钠摄入增加2型糖尿病合并CKD患者心衰和心血管死亡风险。
- 卡格列净可降低低正常钠摄入者的心血管风险,高钠摄入者未获益。
- 卡格列净的肾脏保护作用不受饮食钠摄入水平影响。
核心结论
- 在2型糖尿病合并CKD患者中,低正常钠摄入增加心衰和心血管死亡风险,但不影响肾脏结局。
- 卡格列净减轻低正常钠摄入者的心血管风险升高,且无论钠摄入高低均提供肾脏保护。
研究设计与样本
- CREDENCE试验事后分析,中位随访2.6年。
- 纳入2573例2型糖尿病合并CKD患者,随机接受卡格列净100 mg或安慰剂。
- 通过经验证公式从尿液估算每日钠摄入,分为低正常钠组(n=1286)和高钠组(n=1287)。
主要发现
- 安慰剂组中,低正常钠摄入者心衰/心血管死亡风险高于高钠摄入者(adjHR 1.56,95%CI 1.10–2.23)。
- 卡格列净显著降低低正常钠组心衰/心血管死亡风险(adjHR 0.48,95%CI 0.33–0.70),高钠组无显著降低(adjHR 1.05,95%CI 0.73–1.53)。
- 单纯心衰结局呈现相似模式。
- 钠摄入对肾脏结局无影响,卡格列净在低正常钠组和高钠组均降低肾脏风险。
- 钠摄入和卡格列净均未影响全因死亡。
临床怎么用
- 对2型糖尿病合并CKD患者,评估饮食钠摄入可能有助于识别心血管高风险个体。
- 低正常钠摄入者使用卡格列净可显著降低心衰和心血管死亡风险。
- 卡格列净的肾脏保护作用不依赖于饮食钠摄入水平。
局限性
- 为事后分析,结果需前瞻性研究验证。
- 钠摄入通过尿液公式估算,非直接饮食测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiovascular and renal protection in type 2 diabetes and chronic kidney disease (CKD). Although both excess and restricted sodium intake are linked to adverse outcomes, the interaction of sodium intake with SGLT2 inhibitors has not been explored. This study aimed to examine how dietary sodium intake affects cardiorenal outcomes and whether canagliflozin modifies these effects. METHODS: A post hoc analysis of the CREDENCE trial (median follow-up 2.6 years) was conducted in individuals with type 2 diabetes and CKD randomised to canagliflozin 100 mg or placebo. Using a validated formula, we estimated daily sodium intake from urine in 2573 participants, divided into low-normal sodium (LNS; n=1286) and high sodium (HS; n=1287) groups. Outcomes included the following: cardiovascular death or hospitalisation for heart failure; heart failure alone; a composite renal outcome; and all-cause death. Cox models were adjusted for confounders. Sodium intake was additionally analysed as a continuous variable to assess non-linearity. RESULTS: In the placebo group, LNS intake increased the risk of heart failure/cardiovascular death vs HS (adjusted HR [adjHR] 1.56 [95% CI 1.10, 2.23]). Canagliflozin significantly reduced this risk in the LNS group (adjHR 0.48 [95% CI 0.33, 0.70]) but not in the HS group (adjHR 1.05 [95% CI 0.73, 1.53]). Similar patterns were seen for heart failure alone. Sodium intake had no effect on renal outcomes, while canagliflozin reduced renal risk in both the LNS group and the HS group. Neither sodium intake nor canagliflozin influenced all-cause mortality. Continuous modelling revealed a near-linear rise in heart failure/cardiovascular death risk as sodium intake decreased in placebo recipients, while this gradient was flattened with canagliflozin. CONCLUSIONS/INTERPRETATION: In individuals with type 2 diabetes and CKD, LNS intake increases the risk of heart failure and cardiovascular death, while renal outcomes are unaffected by sodium intake. Canagliflozin mitigates the increased cardiovascular risk in individuals with LNS intake, while offering renal protection irrespective of dietary sodium. TRIAL REGISTRATION: Clinicaltrial.gov NCT02065791.
引用
- Chiriacò M, Tricò D, Giannoni A, et al. Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial. Diabetologia. 2026. PMID: 41817689. doi:10.1007/s00125-026-06705-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。